Dr Alfonso Pierola meets with ecancer at ASH 2016 to discuss the clinical utility of next generation sequencing to determine actionable mutations in myelodysplastic syndrome.

She describes how, while targeted therapies have been successful in other tumour types, only a small proportion of MDS patients sequenced had a known mutational driver that might justify their involvement in further clinical trials.

Overall Dr Pierola describes the inclusion of sequencing as in its infancy for MDS, and looks forward to future development based on a refined pool of targets.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.